Trial Profile
Faslodex Specific Clinical Experience Investigation for Long-term Use
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 23 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
- 18 Jan 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.